PVRIG/CD112R recombinant proteins and antibodies

Poliovirus Receptor-Related Immunoglobulin Domain (PVRIG), also known as CD112R, is an immune checkpoint molecule belonging to the immunosuppressive receptor family, expressed widely on T cells and immune cells in the tumor microenvironment. PVRIG plays a crucial role in regulating immune suppression by interacting with its ligand, PVRL2 (also known as Nectin-2). This interaction is involved in tumor immune evasion, as PVRIG, in synergy with other immune checkpoint receptors such as PD-1 and CTLA-4, inhibits T cell activity, allowing tumor cells to escape immune surveillance. PVRIG is highly expressed in several malignancies, including melanoma, lung cancer, liver cancer, and gastric cancer, indicating its potential as an important immune checkpoint target.

The mechanism of action of PVRIG is through the binding to its ligand PVRL2, which suppresses T cell immune responses and reduces the ability of T cells to attack tumor cells. Therefore, inhibiting the interaction between PVRIG and PVRL2 can restore T cell anti-tumor activity and enhance the immune system’s ability to recognize and eliminate tumor cells. Compared to other immune checkpoint molecules, PVRIG may have a unique inhibitory mechanism, making it a promising target for next-generation immunotherapy.

Currently, ongoing drug development targeting PVRIG is primarily focused on monoclonal antibody therapies. By developing PVRIG monoclonal antibodies, scientists aim to block the interaction between PVRIG and PVRL2, thereby restoring T cell anti-tumor immune responses. Additionally, some companies are exploring the combination of PVRIG-targeted therapies with other immune checkpoint inhibitors (such as PD-1 and CTLA-4) to enhance therapeutic efficacy.
Several pharmaceutical companies have entered the field of PVRIG-targeted research and development. Notable companies such as Merck, Sanofi, and Gilead have invested resources in developing PVRIG-related immunotherapies. These companies have made progress in the development of PVRIG monoclonal antibodies and are conducting clinical trials to evaluate the combined effects of PVRIG-targeted therapy with other immunotherapies. Their goal is to provide new treatment options for cancer patients, especially in cases where traditional immunotherapies are ineffective or less effective.

To assist in the development of PVRIG targeted therapies, DIMA BIOTECH can now provide a full range of products and services for PVRIG targets. Products include active PVRIG recombinant proteins, full-length PVRIG proteins, PVRIG reference antibodies, and FC-verified monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of PVRIG biotherapy, DIMA BIOTECH has also prepared a PVRIG target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple PVRIG IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.